Exenatide extended-release; clinical trials, patient preference, and economic considerations
Sheila A DoggrellSchool of Biomedical Sciences, Faculty of Health, Queensland University of Technology, Brisbane, AustraliaAbstract: Type 2 diabetes remains an escalating problem worldwide, despite a range of treatments being available. The revelation that insulin secretion is under the control of a...
Main Author: | Doggrell SA |
---|---|
Format: | Article |
Language: | English |
Published: |
Dove Medical Press
2013-01-01
|
Series: | Patient Preference and Adherence |
Online Access: | http://www.dovepress.com/exenatide-extended-release-clinical-trials-patient-preference-and-econ-a11907 |
Similar Items
-
Exenatide extended-release: a once weekly treatment for patients with type 2 diabetes
by: Mann KV, et al.
Published: (2014-06-01) -
Clinical outcomes, not clinical utility, should be the major consideration for saxagliptin with or without metformin
by: Doggrell SA
Published: (2014-04-01) -
Pharmalogical effects and results of clinical trials of the first incretinomimetic exenatide
by: Alexander Sergeevich Ametov, et al.
Published: (2011-09-01) -
Exenatide once weekly: clinical outcomes and patient satisfaction
by: Biju Jose1, et al.
Published: (2010-08-01) -
Exenatide Microspheres for Monthly Controlled-Release Aided by Magnesium Hydroxide
by: Yuxuan Ge, et al.
Published: (2021-05-01)